Capstone Therapeutics Corp.’s Lock-Up Period Will End on September 2nd (NASDAQ:CAPS)

Capstone Therapeutics’ (NASDAQ:CAPS) lock-up period is set to expire on Tuesday, September 2nd. Capstone Therapeutics had issued 1,250,000 shares in its initial public offering on March 6th. The total size of the offering was $5,000,000 based on an initial share price of $4.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Capstone Therapeutics to a “sell” rating in a report on Friday, June 6th.

Capstone Therapeutics Price Performance

Capstone Therapeutics stock opened at $1.71 on Tuesday. The business’s 50 day moving average price is $1.51. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.41 and a current ratio of 0.97. Capstone Therapeutics has a fifty-two week low of $0.9609 and a fifty-two week high of $16.18.

Capstone Therapeutics (NASDAQ:CAPS) last posted its earnings results on Friday, August 15th. The company reported ($0.13) earnings per share for the quarter. The business had revenue of $12.85 million for the quarter.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism.